<?xml version="1.0" encoding="UTF-8"?>
<ref id="B209-microorganisms-07-00133">
 <label>209.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Reisinger</surname>
    <given-names>E.C.</given-names>
   </name>
   <name>
    <surname>Tschismarov</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Beubler</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Wiedermann</surname>
    <given-names>U.</given-names>
   </name>
   <name>
    <surname>Firbas</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Loebermann</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Pfeiffer</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Muellner</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Tauber</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Ramsauer</surname>
    <given-names>K.</given-names>
   </name>
  </person-group>
  <article-title>Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial</article-title>
  <source>Lancet</source>
  <year>2018</year>
  <volume>392</volume>
  <fpage>2718</fpage>
  <lpage>2727</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32488-7</pub-id>
  <pub-id pub-id-type="pmid">30409443</pub-id>
 </element-citation>
</ref>
